For: | Shirin H, Sharvit E, Aeed H, Gavish D, Bruck R. Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats. World J Gastroenterol 2013; 19(2): 241-248 [PMID: 23345947 DOI: 10.3748/wjg.v19.i2.241] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v19/i2/241.htm |
Number | Citing Articles |
1 |
Enas S. Nabih, Omnyah A. El-kharashi. Targeting HMGB1/TLR4 axis and miR-21 by rosuvastatin: role in alleviating cholestatic liver injury in a rat model of bile duct ligation. Naunyn-Schmiedeberg's Archives of Pharmacology 2019; 392(1): 37 doi: 10.1007/s00210-018-1560-y
|
2 |
Ganesh Singh Bhakuni, Onkar Bedi, Jitender Bariwal, Rahul Deshmukh, Puneet Kumar. Animal models of hepatotoxicity. Inflammation Research 2016; 65(1): 13 doi: 10.1007/s00011-015-0883-0
|
3 |
Deepika Bhatia, Yogeeta Yogeeta, Pradeep Goyal, Atul Kabra. Development on Animal Models for Drug/Chemical Induced Liver Injury. Biomedical and Pharmacology Journal 2023; 16(1): 131 doi: 10.13005/bpj/2595
|
4 |
Hui Li. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Digestive and Liver Disease 2022; 54(5): 598 doi: 10.1016/j.dld.2021.07.006
|
5 |
Thit Mynster Kronborg, Henriette Ytting, Lise Hobolth, Søren Møller, Nina Kimer. Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.718896
|
6 |
Ya. Novogrodskaya, A. Astrowskaja, R. Kravchuk, Ye. Doroshenko, I. Huliai, A. Aleschyk, S. Shalesnaja, M. Kurbat. THE METHOD OF MODELLING OF EXPERIMENTAL THIOACETAMIDE LIVER DAMAGE IN RATS. Hepatology and Gastroenterology 2020; 4(1): 90 doi: 10.25298/2616-5546-2020-4-1-90-95
|
7 |
Qamar Niaz, Seyed Mohammad Tavangar, Sania Mehreen, Mahmoud Ghazi-Khansari, Farahnaz Jazaeri. Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats. Life Sciences 2022; 308: 120966 doi: 10.1016/j.lfs.2022.120966
|
8 |
Alyaa Hessin, Rehab Hegazy, Azza Hassan, Nemat Yassin, Sanaa Kenawy. Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats. Open Access Macedonian Journal of Medical Sciences 2015; 3(2): 195 doi: 10.3889/oamjms.2015.038
|
9 |
Elham Nozari, Ali Moradi, Morteza Samadi. Effect of Atorvastatin, Curcumin, and Quercetin on miR-21 and miR-122 and their correlation with TGFβ1 expression in experimental liver fibrosis. Life Sciences 2020; 259: 118293 doi: 10.1016/j.lfs.2020.118293
|
10 |
Tracey G. Simon, Lindsay Y. King, Hui Zheng, Raymond T. Chung. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. Journal of Hepatology 2015; 62(1): 18 doi: 10.1016/j.jhep.2014.08.013
|
11 |
Yosra M. Magdy, Omnyah A. El-Kharashi, Dalia A.A. El-Waseef, Enas S. Nabih, Abeer A. Abd El Samad. Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy. Experimental and Molecular Pathology 2018; 105(3): 293 doi: 10.1016/j.yexmp.2018.10.004
|
12 |
Walaa H. El-Maadawy, S. H. Seif el-Din, S. M. Ezzat, O. A. Hammam, M. M. Safar, S. Saleh, N. M. El-Lakkany. Rutin Ameliorates Hepatic Fibrosis via Targeting Hepatic Stellate Cells’ Activation, Proliferation and Apoptosis. Journal of Herbs, Spices & Medicinal Plants 2021; 27(3): 322 doi: 10.1080/10496475.2021.1911905
|
13 |
Sohaila Abd El-Hameed, Iman Ibrahim, Walaa Awadin, Ahmed El-Shaieb. Assessment of single and combined administration of ubiquinone and lactoferrin on histopathology, ultrastructure, oxidative stress, and WNT4 expression gene induced by thioacetamide on hepatorenal system of adult male rats. Beni-Suef University Journal of Basic and Applied Sciences 2024; 13(1) doi: 10.1186/s43088-024-00494-w
|
14 |
Neelam Singh, Puneet Gupta, Charu Bharti, Sadish Kumar Shanmugam. Evaluation of Hepatoprotective Efficacy of a Polyherbal Unani Formulation
Majoon-Najah against Cadmium Chloride-induced Liver Damage. Current Drug Research Reviews 2023; 15(2): 188 doi: 10.2174/2589977515666221207141645
|
15 |
Asmaa Ramadan Abdel-Sattar, Ali Ahmed Abo-Saif, Amira M. Aboyoussef. Nicorandil and atorvastatin attenuate carbon tetrachloride – induced liver fibrosis in rats. Immunopharmacology and Immunotoxicology 2020; 42(6): 582 doi: 10.1080/08923973.2020.1830104
|
16 |
Tracey G. Simon, Hector Bonilla, Peng Yan, Raymond T. Chung, Adeel A. Butt. Atorvastatin and fluvastatin are associated with dose‐dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology 2016; 64(1): 47 doi: 10.1002/hep.28506
|
17 |
Tracey G Simon, Adeel A Butt. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World Journal of Gastroenterology 2015; 21(27): 8293-8303 doi: 10.3748/wjg.v21.i27.8293
|
18 |
Sayed H. Seif el-Din, Olfat A. Hammam, Shahira M. Ezzat, Samira Saleh, Marwa M. Safar, Walaa H. El-Maadawy, Naglaa M. El-Lakkany. Hydroxysafflor yellow A protects against thioacetamide-induced liver fibrosis in rats via suppressing proinflammatory/fibrogenic mediators and promoting hepatic stellate cell senescence and apoptosis. Asian Pacific Journal of Tropical Biomedicine 2023; 13(8): 348 doi: 10.4103/2221-1691.383689
|
19 |
Yangmi Kim, Eun Jeoung Lee, Hee Kyung Jang, Chan Hyung Kim, Dae‐Ghon Kim, Joung‐Ho Han, Seon Mee Park. Statin pretreatment inhibits the lipopolysaccharide‐induced epithelial‐mesenchymal transition via the downregulation of toll‐like receptor 4 and nuclear factor‐κB in human biliary epithelial cells. Journal of Gastroenterology and Hepatology 2016; 31(6): 1220 doi: 10.1111/jgh.13230
|
20 |
Jose Ignacio Vargas, Marco Arrese, Vijay H. Shah, Juan Pablo Arab. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. Current Gastroenterology Reports 2017; 19(9) doi: 10.1007/s11894-017-0584-7
|
21 |
Zahra Goodarzi, Esmaeil Karami, Sedighe Yousefi, Alireza Dehdashti, Ahmad Reza Bandegi, Ali Ghanbari. Hepatoprotective effect of atorvastatin on Cadmium chloride induced hepatotoxicity in rats. Life Sciences 2020; 254: 117770 doi: 10.1016/j.lfs.2020.117770
|
22 |
Ralf Weiskirchen. Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step. Frontiers in Pharmacology 2016; 6 doi: 10.3389/fphar.2015.00303
|